Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors

被引：72

作者：

Bamborough, Paul ^{[1
]}

Chung, Chun-wa ^{[1
]}

Furze, Rebecca C. ^{[2
]}

Grandi, Paola ^{[4
]}

Michon, Anne-Marie ^{[4
]}

Sheppard, Robert J. ^{[2
]}

Barnett, Heather ^{[3
]}

Diallo, Hawa ^{[2
]}

Dixon, David P. ^{[1
]}

Douault, Clement ^{[2
]}

Jones, Emma J. ^{[1
]}

Karamshi, Bhumika ^{[1
]}

Mitchell, Darren J. ^{[2
]}

Prinjha, Rab K. ^{[2
]}

Rau, Christina ^{[4
]}

Watson, Robert J. ^{[2
]}

Wemer, Thilo ^{[4
]}

Demont, Emmanuel H. ^{[2
]}

机构：

[1] GlaxoSmithKline Med Res Ctr, Mol Discovery Res, Stevenage SG1 2NY, Herts, England

[2] GlaxoSmithKline Med Res Ctr, Epinova Discovery Performance Unit, Stevenage SG1 2NY, Herts, England

[3] GlaxoSmithKline Med Res Ctr, Flexible Discovery Unit, Stevenage SG1 2NY, Herts, England

[4] GlaxoSmithKline, Mol Discovery Res, Cellzome GmbH, D-69117 Heidelberg, Germany

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 58卷 / 15期

关键词：

DISCOVERY;

D O I：

10.1021/acs.jmedchem.5b00773

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

ATAD2 is a bromodomain-containing protein whose overexpression is linked to poor outcomes in a number of different cancer types. To date, no potent and selective inhibitors of the bromodomain have been reported. This article describes the structure-based optimization of a series of naphth-yridones from micromolar leads with no selectivity over the BET bromodomains to inhibitors with sub-100 nM ATAD2 potency and 100-fold BET selectivity.

引用

页码：6151 / 6178

页数：28

共 50 条

[1] Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode
Lucas, Simon C. C.
Atkinson, Stephen J.
Bamborough, Paul
Barnett, Heather
Chung, Chun-wa
Gordon, Laurie
Mitchell, Darren J.
Phillipou, Alexander
Prinjha, Rab K.
Sheppard, Robert J.
Tomkinson, Nicholas C. O.
Watson, Robert J.
Demont, Emmanuel H.
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (10) : 5212 - 5241
[2] The identification of new ATAD2 bromodomain inhibitors: the application of combined ligand and structure-based virtual screening
Sepehri, B.
Ghavami, R.
SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2017, 28 (12) : 957 - 971
[3] Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening
Yao, Dahong
Zhang, Jin
Wang, Jinhui
Pan, Dabo
He, Zhendan
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 713 - 725
[4] Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain
Chaikuad, Apirat
Petros, Andrew M.
Fedorov, Oleg
Xu, Jing
Knapp, Stefan
MEDCHEMCOMM, 2014, 5 (12) : 1843 - 1848
[5] Fragment-Based Screening of the Bromodomain of ATAD2
Harner, Mary J.
Chauder, Brian A.
Phan, Jason
Fesik, Stephen W.
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (22) : 9687 - 9692
[6] Chemical synthesis of the ATAD2 bromodomain
Creech, Gardner S.
Paresi, Chelsea
Li, Yue-Ming
Danishefsky, Samuel J.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (08) : 2891 - 2896
[7] A Chemical Probe for the ATAD2 Bromodomain
Bamborough, Paul
Chung, Chun-wa
Demont, Emmanuel H.
Furze, Rebecca C.
Bannister, Andrew J.
Che, Ka Hing
Diallo, Hawa
Douault, Clement
Grandi, Paola
Kouzarides, Tony
Michon, Anne-Marie
Mitchell, Darren J.
Prinjha, Rab K.
Rau, Christina
Robson, Samuel
Sheppard, Robert J.
Upton, Richard
Watson, Robert J.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (38) : 11382 - 11386
[8] Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors
Demont, Emmanuel H.
Chung, Chun-wa
Furze, Rebecca C.
Grandi, Paola
Michon, Anne-Marie
Wellaway, Chris
Barrett, Nathalie
Bridges, Angela M.
Craggs, Peter D.
Diallo, Hawa
Dixon, David P.
Douault, Clement
Emmons, Amanda J.
Jones, Emma J.
Karamshi, Bhumika V.
Locke, Kelly
Mitchell, Darren J.
Mouzon, Bernadette H.
Prinjha, Rab K.
Roberts, Andy D.
Sheppard, Robert J.
Watson, Robert J.
Bamborough, Paul
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (14) : 5649 - 5673
[9] Potent and isoform-selective ATAD2 bromodomain inhibitor with unprecedented chemical structure and mode of action
Fernandez-Montalvan, Amaury E.
Berger, Markus
Kuropka, Benno
Koo, Seong Joo
Badock, Volker
Weiske, Joerg
Holton, Simon J.
Chaikuad, Apirat
Diaz-Saez, Laura
Bennett, James
Federov, Oleg
Huber, Kilian
Centrella, Paolo
Clark, Matthew A.
Dumelin, Christoph E.
Sigel, Eric A.
Soutter, Holly S.
Troast, Dawn M.
Zhang, Ying
Cuozzo, John W.
Keefe, Anthony D.
Roche, Didier
Rodeschini, Vincent
Huebner, Jan
Weinmann, Hilmar
Hartung, Ingo V.
Gorjanacz, Matyas
CANCER RESEARCH, 2017, 77
[10] Genomic alteration of bromodomain protein ATAD2 in cancer
Takeda, Tomoyo
Matsumura, Yuta
Nagasaki, Hirotoshi
Eguchi, Ken
Takatsuka, Miki
Shinkai, Yoichi
Nakagawa, Hiroyuki
Kawashima, Hitoshi
Ueno, Hiroyuki
Li, Chiang J.
CANCER RESEARCH, 2014, 74 (19)

← 1 2 3 4 5 →